Your browser is no longer supported. Please, upgrade your browser.
DA32 Life Science Tech Acquisition Corp.
Index- P/E- EPS (ttm)- Insider Own7.02% Shs Outstand20.65M Perf Week-0.61%
Market Cap199.91M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month-1.72%
Income- PEG- EPS next Q- Inst Own91.59% Short Float- Perf Quarter-0.81%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.62 Perf Half Y-
Book/sh-0.12 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range9.65 - 10.26 Perf YTD-1.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.64% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low0.32% ATR0.08
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)43.59 Volatility0.00% 0.58%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close9.72
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume20.15K Price9.68
Recom- SMA20-0.66% SMA50-1.14% SMA200-1.47% Volume10 Change-0.40%
Jul-30-21 04:05PM  
Jul-27-21 08:37PM  
DA32 Life Science Tech Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors. DA32 Life Science Tech Acquisition Corp. was incorporated in 2021 and is based in New York, New York.